Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol. / Khan, Sabrina; Deen, Marie; Hougaard, Anders; Amin, Faisal Mohammad; Ashina, Messoud.
I: Cephalalgia : an international journal of headache, Bind 38, Nr. 5, 2018, s. 892-903.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol
AU - Khan, Sabrina
AU - Deen, Marie
AU - Hougaard, Anders
AU - Amin, Faisal Mohammad
AU - Ashina, Messoud
PY - 2018
Y1 - 2018
N2 - Introduction The phosphodiesterase-3-inhibitor cilostazol induces migraine-like attacks in patients with migraine without aura, and may be used as a pharmacological trigger in human experimental models of migraine. However, the reproducibility of cilostazol-induced migraine-like attacks has never been investigated. Methods We performed a post-hoc analysis of clinical data from two brain-imaging studies including subjects who had received cilostazol 200 mg orally. Only subjects who developed migraine-like attacks on study day 1 were included on study day 2. After cilostazol ingestion, subjects and the investigator recorded headache intensity and characteristics once every hour on a purpose-developed questionnaire. Primary end-points included incidence and time to onset of migraine-like attacks between two separate study days. Results Thirty-four subjects completed both experimental days and were included in this study. Thirty-four out of 34 subjects (100%) developed migraine-like attacks after cilostazol ingestion on both study days 1 and 2. Time to onset of migraine was five hours (range 1-8 hours) on study day 1 and four hours (range 1-8 hours) on study day 2, p = 0.16. We found no difference in median peak headache score, median time to peak headache score, or median time to intake of rescue medication between study days 1 and 2. Conclusion A second-time administration of cilostazol reproduces migraine-like attacks in all subjects who report an attack after their first cilostazol induction. There was no difference in time to migraine onset between separate inductions. Experimental migraine provocation using cilostazol is a highly efficient and useful approach for studying the ictal phase of migraine without aura.
AB - Introduction The phosphodiesterase-3-inhibitor cilostazol induces migraine-like attacks in patients with migraine without aura, and may be used as a pharmacological trigger in human experimental models of migraine. However, the reproducibility of cilostazol-induced migraine-like attacks has never been investigated. Methods We performed a post-hoc analysis of clinical data from two brain-imaging studies including subjects who had received cilostazol 200 mg orally. Only subjects who developed migraine-like attacks on study day 1 were included on study day 2. After cilostazol ingestion, subjects and the investigator recorded headache intensity and characteristics once every hour on a purpose-developed questionnaire. Primary end-points included incidence and time to onset of migraine-like attacks between two separate study days. Results Thirty-four subjects completed both experimental days and were included in this study. Thirty-four out of 34 subjects (100%) developed migraine-like attacks after cilostazol ingestion on both study days 1 and 2. Time to onset of migraine was five hours (range 1-8 hours) on study day 1 and four hours (range 1-8 hours) on study day 2, p = 0.16. We found no difference in median peak headache score, median time to peak headache score, or median time to intake of rescue medication between study days 1 and 2. Conclusion A second-time administration of cilostazol reproduces migraine-like attacks in all subjects who report an attack after their first cilostazol induction. There was no difference in time to migraine onset between separate inductions. Experimental migraine provocation using cilostazol is a highly efficient and useful approach for studying the ictal phase of migraine without aura.
KW - Adult
KW - Cilostazol/adverse effects
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Migraine Disorders/chemically induced
KW - Phosphodiesterase 3 Inhibitors/adverse effects
KW - Reproducibility of Results
KW - Time Factors
KW - Young Adult
U2 - 10.1177/0333102417719753
DO - 10.1177/0333102417719753
M3 - Journal article
C2 - 28677994
VL - 38
SP - 892
EP - 903
JO - Cephalalgia
JF - Cephalalgia
SN - 0800-1952
IS - 5
ER -
ID: 215867878